secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2022-11-28T23:59:59+00:00
Accession:  0001193125-22-292703
Event type: regulatory
Sentiment:  neutral
Materiality: 0.30
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

AADI Bioscience regains compliance with Nasdaq audit committee independence rule
--------------------------------------------------------------------------------

- Non-compliance resulted from Dr. Karin Hehenberger not qualifying as independent per Nasdaq Listing Rule 5605(c)(2)(A).
- Board removed Hehenberger from Audit Committee and appointed Caley Castelein, M.D., who meets independence requirements.
- Audit Committee now consists of Emma Reeve (chair), Richard Maroun, and Caley Castelein; company believes compliance restored.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522292703/0001193125-22-292703-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522292703/d425406d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-292703

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer